Advancements in Immune Checkpoint-Based Immunotherapy for Triple-Negative Breast Cancer
Current Issues in Molecular Biology · 12.06.2026 · 48 (6) · 615
DOI: 10.3390/cimb48060615 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Current Issues in Molecular Biology, online erschienen am 12.06.2026. Verfasst von Dexian Wei und 4 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Drug Regulatory Sciences, National Institutes for Food and Drug Control, Beijing 102629, China. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 208 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: State Key Laboratory of Drug Research, State Key Laboratory of Drug Regulatory Sciences.
Abstract (Originalsprache)
Triple-negative breast cancer (TNBC), characterized by the lack of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) expression, is a highly aggressive molecular subtype with high recurrence and metastasis rates. Due to the absence of reliable molecular targets, surgery combined with chemotherapy remains the mainstay of clinical treatment. In recent years, immunotherapy has provided new strategies for TNBC management. Immune checkpoints are key regulatory molecules that maintain immune homeostasis, and blocking these checkpoints can restore T cell activity and enhance tumor cell killing. Immune checkpoint inhibitors (ICIs) have demonstrated clinical benefit, particularly in combination with chemotherapy for patients with locally advanced or metastatic TNBC. This review focuses on immune checkpoint–based immunotherapy in TNBC, providing an overview from mechanistic insights to clinical applications and emerging therapeutic strategies. In addition to ICIs, we discuss alternative approaches, such as bispecific antibodies, antibody–drug conjugates (ADCs), chimeric antigen receptor T cell (CAR-T) therapy, tumor vaccines, and oncolytic viruses (OVs), highlighting their current research progress and clinical applications in TNBC treatment.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- State Key Laboratory of Drug Regulatory Sciences, National Institutes for Food and Drug Control, Beijing 102629, China.
- Department of Experimental Pharmacology and Toxicology, School of Pharmaceutical Sciences, Jilin University, Changchun 130021, China.
Förderung
- State Key Laboratory of Drug Research
- State Key Laboratory of Drug Regulatory Sciences
Zitieren
APA
Wei, D., Zhang, Y., Wu, Y., Ren, L., & He, Q. (2026). Advancements in Immune Checkpoint-Based Immunotherapy for Triple-Negative Breast Cancer. Current Issues in Molecular Biology, 48(6), 615. https://doi.org/10.3390/cimb48060615
Vancouver
Wei D, Zhang Y, Wu Y, Ren L, He Q. Advancements in Immune Checkpoint-Based Immunotherapy for Triple-Negative Breast Cancer. Current Issues in Molecular Biology. 2026;48(6):615. doi:10.3390/cimb48060615
BibTeX
@article{Wei2026,
author = {Wei, Dexian and Zhang, Yuan and Wu, Yanlin and Ren, Liqun and He, Qing},
title = {Advancements in Immune Checkpoint-Based Immunotherapy for Triple-Negative Breast Cancer},
journal = {Current Issues in Molecular Biology},
year = {2026},
volume = {48},
number = {6},
pages = {615},
doi = {10.3390/cimb48060615}
}
EUVIMED